Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma
2
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Background/Aims: This study aimed to investigate whether everolimus (EVR) affects long-term survival after liver transplantation (LT) in patients with hepatocellular carcinoma (HCC). Methods: The data from 303 consecutive patients with HCC who had undergone LT from January 2012 to July 2018 were retrospectively reviewed. The patients were divided into two groups: 1) patients treated with EVR in combination with calcineurin inhibitors (CNIs) (EVR group; n=114) and 2) patients treated with CNI-based therapy without EVR (non-EVR group; n=189). Time to recurrence (TTR) and overall survival (OS) after propensity score (PS) matching were compared between the groups, and prognostic factors for TTR and OS were evaluated. Results: The EVR group exhibited more aggressive tumor biology than the non-EVR group, such as a higher number of tumors (P=0.003), a higher prevalence of microscopic vascular invasion (P=0.017) and exceeding Milan criteria (P=0.029). Compared with the PS-matched non-EVR group, the PS-matched EVR group had significantly better TTR (P<0.001) and OS (P<0.001). In multivariable analysis, EVR was identified as an independent prognostic factor for TTR (hazard ratio [HR], 0.248; P=0.001) and OS (HR, 0.145; P<0.001). Conclusions: Combined with CNIs, EVR has the potential to prolong long-term survival in patients undergoing LT for HCC. These findings warrant further investigation in a well-designed prospective study.
Abstract
Background/Aims: This study aimed to investigate whether everolimus (EVR) affects long-term survival after liver transplantation (LT) in patients with hepatocellular carcinoma (HCC). Methods: The data from 303 consecutive patients with HCC who had undergone LT from January 2012 to July 2018 were retrospectively reviewed. The patients were divided into two groups: 1) patients treated with EVR in combination with calcineurin inhibitors (CNIs) (EVR group; n=114) and 2) patients treated with CNI-based therapy without EVR (non-EVR group; n=189). Time to recurrence (TTR) and overall survival (OS) after propensity score (PS) matching were compared between the groups, and prognostic factors for TTR and OS were evaluated. Results: The EVR group exhibited more aggressive tumor biology than the non-EVR group, such as a higher number of tumors (P=0.003), a higher prevalence of microscopic vascular invasion (P=0.017) and exceeding Milan criteria (P=0.029). Compared with the PS-matched non-EVR group, the PS-matched EVR group had significantly better TTR (P<0.001) and OS (P<0.001). In multivariable analysis, EVR was identified as an independent prognostic factor for TTR (hazard ratio [HR], 0.248; P=0.001) and OS (HR, 0.145; P<0.001). Conclusions: Combined with CNIs, EVR has the potential to prolong long-term survival in patients undergoing LT for HCC. These findings warrant further investigation in a well-designed prospective study.
참고문헌 (31)
- Pavel MC, "Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation : future directions", World J Gastroenterol, 24, pp.3626~3636 (2018)
- Shimamura T, "Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey : the 5-5-500 rule-a retrospective study", Transpl Int, 32, pp.356~368 (2019)
- Chu Kevin Ka-Wan, "Expanding Indications for Liver Transplant: Tumor and Patient Factors", Gut and Liver, 15(1), pp.19~30 (2021), 거트앤리버 소화기연관학회협의회[DOI]
- Clavien PA, "Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report", Lancet Oncol, 13, pp.e11~e22 (2012)
- de’Angelis N, "Managements of recurrent hepatocellular carcinoma after liver transplantation : a systematic review", World J Gastroenterol, 21, pp.11185~11198 (2015)
- Schlansky B, "Promise and pitfalls of using α-fetoprotein in liver transplantation allocation for hepatocellular carcinoma", JAMA Surg, 152, pp.64~65 (2017)
- Mazzaferro V, "Alpha-fetoprotein in liver transplantation for hepatocellular carcinoma : the lower, the better", Hepatology, 68, pp.775~777 (2018)
- Tamura S, "Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation", Arch Surg, 136, pp.25~30 (2001)
- Decaens T, "Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma : a multicenter study of 412 patients", World J Gastroenterol, 12, pp.7319~7325 (2006)
- Lim KC, "Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria", Ann Surg, 254, pp.108~113 (2011)
- Kang I, "Subclassification of microscopic vascular invasion in hepatocellular carcinoma", Ann Surg (2020)[DOI]
- Vivarelli M, "Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma : key role of immunosuppression", Liver Transpl, 11, pp.497~503 (2005)
- Vivarelli M, "Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors : reassessment of risk factors for tumor recurrence", Ann Surg, 248, pp.857~862 (2008)
- Grigg SE, "Systematic review with meta-analysis : sirolimus-or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma", Aliment Pharmacol Ther, 49, pp.1260~1273 (2019)
- Meier-Kriesche HU, "Immunosuppression : evolution in practice and trends, 1994-2004", Am J Transplant, 6(5 Pt 2), pp.1111~1131 (2006)
- Hojo M, "Cyclosporine induces cancer progression by a cell-autonomous mechanism", Nature, 397, pp.530~534 (1999)
- Vivarelli M, "Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma", Transplantation, 89, pp.227~231 (2010)
- De Simone P, "Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients : a randomized controlled trial", Am J Transplant, 12, pp.3008~3020 (2012)
- Fischer L, "Three-year outcomes in de novo liver transplant patients receiving everolimus with reduced tacrolimus : follow-up results from a randomized, multicenter study", Transplantation, 99, pp.1455~1462 (2015)
- Semela D, "Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma", J Hepatol, 46, pp.840~848 (2007)
- Toso C, "Sirolimusbased immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma", Hepatology, 51, pp.1237~1243 (2010)
- Holdaas H, "Everolimus and malignancy after solid organ transplantation : a clinical update", J Transplant, 2016, pp.4369574~ (2016)
- Jin YP, "Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus", Am J Transplant, 14, pp.806~819 (2014)
- Klawitter J, "Everolimus and sirolimus in transplantation-related but different", Expert Opin Drug Saf, 14, pp.1055~1070 (2015)
- Jeng LB, "Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients : 12-month results of a randomized multicenter study", Am J Transplant, 18, pp.1435~1446 (2018)
- De Simone P, "Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients : a prospective, randomized, multicenter trial", Liver Transpl, 15, pp.1262~1269 (2009)
- Knight RJ, "Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients", Clin Transplant, 21, pp.460~465 (2007)
- Toso C, "De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma : long-term outcomes and side effects", Transplantation, 83, pp.1162~1168 (2007)
- Montalbano M, "A retrospective review of liver transplant patients treated with sirolimus from a single center : an analysis of sirolimusrelated complications", Transplantation, 78, pp.264~268 (2004)
- Pommergaard HC, "Vascular invasion and survival after liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry", HPB (Oxford), 20, pp.768~775 (2018)
- Geissler EK, "Sirolimus use in liver transplant recipients with hepatocellular carcinoma : a randomized, multicenter, open-label phase 3trial", Transplantation, 100, pp.116~125 (2016)